vs
CoastalSouth Bancshares, Inc.(COSO)与STANDARD BIOTOOLS INC.(LAB)财务数据对比。点击上方公司名可切换其他公司
CoastalSouth Bancshares, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.1倍($21.3M vs $19.6M),CoastalSouth Bancshares, Inc.净利率更高(31.7% vs -177.4%,领先209.1%),CoastalSouth Bancshares, Inc.自由现金流更多($-5.9M vs $-23.1M)
CoastalSouth Bancshares, Inc.是一家美国区域性银行控股企业,主要通过旗下附属银行开展业务,为美国墨西哥湾沿岸地区的零售客户与中小企业提供存款、消费贷款、商业融资、抵押贷款、财富管理等多元金融服务。
Standard BioTools(原Fluidigm公司)是一家美国生命科学工具企业,主营流式细胞术与组织成像分析用质谱流式系统,以及配套的检测试剂盒与试剂,同时供应自动化基因组分析仪器、各类微流控芯片(又称集成流体电路)及配套试剂耗材,全系列产品及应用场景均可提供定制检测方案与相关服务。
COSO vs LAB — 直观对比
营收规模更大
COSO
是对方的1.1倍
$19.6M
净利率更高
COSO
高出209.1%
-177.4%
自由现金流更多
COSO
多$17.2M
$-23.1M
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $21.3M | $19.6M |
| 净利润 | $6.7M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 41.2% | -168.5% |
| 净利率 | 31.7% | -177.4% |
| 营收同比 | — | -11.5% |
| 净利润同比 | — | -28.8% |
| 每股收益(稀释后) | $0.54 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
COSO
LAB
| Q3 25 | $21.3M | $19.6M | ||
| Q2 25 | $19.9M | $21.8M | ||
| Q1 25 | — | $40.8M | ||
| Q3 24 | — | $22.1M | ||
| Q2 24 | — | $22.5M | ||
| Q1 24 | — | $45.5M | ||
| Q4 23 | — | $28.2M | ||
| Q3 23 | — | $25.4M |
净利润
COSO
LAB
| Q3 25 | $6.7M | $-34.7M | ||
| Q2 25 | $6.0M | $-33.5M | ||
| Q1 25 | — | $-26.0M | ||
| Q3 24 | — | $-26.9M | ||
| Q2 24 | — | $-45.7M | ||
| Q1 24 | — | $-32.2M | ||
| Q4 23 | — | $-19.8M | ||
| Q3 23 | — | $-21.0M |
毛利率
COSO
LAB
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% | ||
| Q4 23 | — | 47.6% | ||
| Q3 23 | — | 44.0% |
营业利润率
COSO
LAB
| Q3 25 | 41.2% | -168.5% | ||
| Q2 25 | 35.4% | -118.1% | ||
| Q1 25 | — | -80.8% | ||
| Q3 24 | — | -120.9% | ||
| Q2 24 | — | -134.5% | ||
| Q1 24 | — | -132.2% | ||
| Q4 23 | — | -75.9% | ||
| Q3 23 | — | -83.5% |
净利率
COSO
LAB
| Q3 25 | 31.7% | -177.4% | ||
| Q2 25 | 30.0% | -153.7% | ||
| Q1 25 | — | -63.8% | ||
| Q3 24 | — | -122.0% | ||
| Q2 24 | — | -203.3% | ||
| Q1 24 | — | -70.6% | ||
| Q4 23 | — | -70.2% | ||
| Q3 23 | — | -82.8% |
每股收益(稀释后)
COSO
LAB
| Q3 25 | $0.54 | $-0.09 | ||
| Q2 25 | $0.57 | $-0.09 | ||
| Q1 25 | — | $-0.07 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.12 | ||
| Q1 24 | — | $-0.27 | ||
| Q4 23 | — | $-0.24 | ||
| Q3 23 | — | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $250.4M | $399.7M |
| 总资产 | $2.3B | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
COSO
LAB
| Q3 25 | — | $129.4M | ||
| Q2 25 | — | $158.6M | ||
| Q1 25 | — | $150.9M | ||
| Q3 24 | — | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | — | $287.1M | ||
| Q4 23 | — | $51.7M | ||
| Q3 23 | — | $79.7M |
总债务
COSO
LAB
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M | ||
| Q4 23 | — | $63.5M | ||
| Q3 23 | — | $64.6M |
股东权益
COSO
LAB
| Q3 25 | $250.4M | $399.7M | ||
| Q2 25 | $209.4M | $424.5M | ||
| Q1 25 | — | $454.6M | ||
| Q3 24 | — | $489.3M | ||
| Q2 24 | — | $510.3M | ||
| Q1 24 | — | $577.3M | ||
| Q4 23 | — | $-148.1M | ||
| Q3 23 | — | $-131.7M |
总资产
COSO
LAB
| Q3 25 | $2.3B | $539.6M | ||
| Q2 25 | $2.2B | $557.0M | ||
| Q1 25 | — | $579.6M | ||
| Q3 24 | — | $681.5M | ||
| Q2 24 | — | $708.7M | ||
| Q1 24 | — | $777.7M | ||
| Q4 23 | — | $323.1M | ||
| Q3 23 | — | $339.3M |
负债/权益比
COSO
LAB
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-5.5M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | $-23.1M |
| 自由现金流率自由现金流/营收 | -27.7% | -118.1% |
| 资本支出强度资本支出/营收 | 1.9% | 4.5% |
| 现金转化率经营现金流/净利润 | -0.82× | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势,按日历期对齐
经营现金流
COSO
LAB
| Q3 25 | $-5.5M | $-22.2M | ||
| Q2 25 | $-16.8M | $-20.7M | ||
| Q1 25 | — | $-30.3M | ||
| Q3 24 | — | $-27.9M | ||
| Q2 24 | — | $-39.0M | ||
| Q1 24 | — | $-62.5M | ||
| Q4 23 | — | $-14.1M | ||
| Q3 23 | — | $-11.4M |
自由现金流
COSO
LAB
| Q3 25 | $-5.9M | $-23.1M | ||
| Q2 25 | $-17.9M | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M | ||
| Q4 23 | — | $-14.1M | ||
| Q3 23 | — | $-12.3M |
自由现金流率
COSO
LAB
| Q3 25 | -27.7% | -118.1% | ||
| Q2 25 | -90.3% | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% | ||
| Q4 23 | — | -50.2% | ||
| Q3 23 | — | -48.6% |
资本支出强度
COSO
LAB
| Q3 25 | 1.9% | 4.5% | ||
| Q2 25 | 5.5% | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | 1.7% | ||
| Q4 23 | — | 0.3% | ||
| Q3 23 | — | 3.6% |
现金转化率
COSO
LAB
| Q3 25 | -0.82× | — | ||
| Q2 25 | -2.82× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COSO
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |